NCT Number: NCT00116467
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia
The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–60 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
University of California, San Francisco, San Francisco, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Initial diagnosis of de novo AML with no preexisting hematologic dysplasia for more than 3 months.
- No prior therapy except leukapheresis or less than 72 hours of hydroxyurea.
Exclusion criteria
- Prior myelodysplastic disorder, or treatment-related leukemia.
- Prior myeloproliferative disease.
- Acute promyelocytic leukemia (APL).
- Prior chemotherapy for a malignant or nonmalignant disorder.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Cell Genesys
Industry
Registry information
Official study title
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line
Important dates
- Study start
- 2001
- Study completion
- 2006
- First posted
- Jun 30, 2005
- Registry last updated
- Dec 24, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
NCT01096602
AML, Acute Myelogenous Leukemia
Boston, Massachusetts, United States
View Trial DetailsOpen-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
NCT02719574
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
Los Angeles, California, United States
View Trial DetailsLILRB4 STAR-T Cell Therapy for Monocytic Leukemia
NCT05739409
Acute Myelogenous Leukemia, Bone Marrow Diseases
Tianjin, Tianjin Municipality, China
View Trial DetailsHaploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
NCT02996773
Actinomycetales Infections, Acute Lymphoblastic Leukemia
Tucson, Arizona, United States
View Trial Details